|
1
|
Gottesman MM, Lavi O, Hall MD and Gillet
J-P: Toward a better understanding of the complexity of cancer drug
resistance. Annu Rev Pharmacol Toxicol. 56:85–102. 2016. View Article : Google Scholar
|
|
2
|
Bergman PJ and Harris D: Radioresistance,
chemoresistance, and apoptosis resistance The past, present, and
future. Vet Clin North Am Small Anim Pract. 27:47–57. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shevde LA and Samant RS: Role of
osteopontin in the pathophysiology of cancer. Matrix Biol.
37:131–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clemente N, Raineri D, Cappellano G,
Boggio E, Favero F, Soluri MF, Dianzani C, Comi C, Dianzani U and
Chiocchetti A: Osteopontin bridging innate and adaptive immunity in
autoimmune diseases. J Immunol Res. 2016:76754372016. View Article : Google Scholar
|
|
5
|
Gu T, Ohashi R, Cui R, Tajima K, Yoshioka
M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, et
al: Osteopontin is involved in the development of acquired
chemo-resistance of cisplatin in small cell lung cancer. Lung
Cancer. 66:176–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang RH, Quan YJ, Chen JH, Wang TF, Xu M,
Ye M, Yuan H, Zhang CJ, Liu XJ and Min ZJ: Osteopontin promotes
cell migration and invasion, and inhibits apoptosis and autophagy
in colorectal cancer by activating the p38 MAPK signaling pathway.
Cell Physiol Biochem. 41:1851–1864. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Y, Jiang W, Wang Y, Wu J, Saiyin H,
Qiao X, Mei X, Guo B, Fang X, Zhang L, et al: Breast cancer
metastasis suppressor 1 regulates hepatocellular carcinoma cell
apoptosis via suppressing osteopontin expression. PLoS One.
7:e429762012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu XL, Lin KJ, Bai AP, Wang WX, Meng XK,
Su XL, Hou MX, Dong PD, Zhang JJ, Wang ZY, et al: Osteopontin
knockdown suppresses the growth and angiogenesis of colon cancer
cells. World J Gastroenterol. 20:10440–10448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi Z, Wang B, Chihanga T, Kennedy MA and
Weber GF: Energy metabolism during anchorage-independence Induction
by osteopontin-c. PLoS One. 9:e1056752014. View Article : Google Scholar
|
|
10
|
Malaponte G, Hafsi S, Polesel J,
Castellano G, Spessotto P, Guarneri C, Canevari S, Signorelli SS,
McCubrey JA and Libra M: Tumor microenvironment in diffuse large
B-cell lymphoma: Matrixmetalloproteinases activation is mediated by
osteopontin overexpression. Biochim Biophys Acta. 1863:483–489.
2016. View Article : Google Scholar
|
|
11
|
Caputo S and Bellone M: Osteopontin and
the immune system: Another brick in the wall. Cell Mol Immunol.
15:405–407. 2018. View Article : Google Scholar
|
|
12
|
Mohammadi S, Ghaffari SH, Shaiegan M,
Zarif MN, Nikbakht M, Akbari Birgani S, Alimoghadam K and
Ghavamzadeh A: Acquired expression of osteopontin selectively
promotes enrichment of leukemia stem cells through
AKT/mTOR/PTEN/β-catenin pathways in AML cells. Life Sci.
152:190–198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bellahcène A, Castronovo V, Ogbureke KUE,
Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked
glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat
Rev Cancer. 8:212–226. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Phillips RJ, Helbig KJ, Van der Hoek KH,
Seth D and Beard MR: Osteopontin increases hepatocellular carcinoma
cell growth in a CD44 dependant manner. World J Gastroenterol.
18:3389–3399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rabenstein M, Vay SU, Flitsch LJ, Fink GR,
Schroeter M and Rueger MA: Osteopontin directly modulates cytokine
expression of primary microglia and increases their survival. J
Neuroimmunol. 299:130–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cook AC, Tuck AB, McCarthy S, Turner JG,
Irby RB, Bloom GC, Yeatman TJ and Chambers AF: Osteopontin induces
multiple changes in gene expression that reflect the six ‘hallmarks
of cancer’ in a model of breast cancer progression. Mol Carcinog.
43:225–236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gimba ER and Tilli TM: Human osteopontin
splicing isoforms: Known roles, potential clinical applications and
activated signaling pathways. Cancer Lett. 331:11–17. 2013.
View Article : Google Scholar
|
|
18
|
Zhang H, Guo M, Chen JH, Wang Z, Du XF,
Liu PX and Li WH: Osteopontin knockdown inhibits αv,β3
integrin-induced cell migration and invasion and promotes apoptosis
of breast cancer cells by inducing autophagy and inactivating the
PI3K/Akt/mTOR pathway. Cell Physiol Biochem. 33:991–1002. 2014.
View Article : Google Scholar
|
|
19
|
Yang L, Wei L, Zhao W, Wang X, Zheng G,
Zheng M, Song X and Zuo W: Down-regulation of osteopontin
expression by RNA interference affects cell proliferation and
chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol Med
Rep. 5:373–376. 2012.
|
|
20
|
Zhang A, Liu Y, Shen Y, Xu Y and Li X:
Osteopontin silencing by small interfering RNA induces apoptosis
and suppresses invasion in human renal carcinoma Caki-1 cells. Med
Oncol. 27:1179–1184. 2010. View Article : Google Scholar
|
|
21
|
Naor D, Wallach-Dayan SB, Zahalka MA and
Sionov RV: Involvement of CD44, a molecule with a thousand faces,
in cancer dissemination. Semin Cancer Biol. 18:260–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Wever O, Demetter P, Mareel M and
Bracke M: Stromal myofibroblasts are drivers of invasive cancer
growth. Int J Cancer. 123:2229–2238. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Polyak K, Haviv I and Campbell IG:
Co-evolution of tumor cells and their microenvironment. Trends
Genet. 25:30–38. 2009. View Article : Google Scholar
|
|
24
|
Kale S, Raja R, Thorat D, Soundararajan G,
Patil TV and Kundu GC: Osteopontin signaling upregulates
cyclooxygenase-2 expression in tumor-associated macrophages leading
to enhanced angiogenesis and melanoma growth via α9β1 integrin.
Oncogene. 33:2295–2306. 2014. View Article : Google Scholar
|
|
25
|
Lin CN, Wang CJ, Chao YJ, Lai M-D and Shan
Y-S: The significance of the co-existence of osteopontin and
tumor-associated macrophages in gastric cancer progression. BMC
Cancer. 15:1282015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shao L, Zhang B, Wang L, Wu L, Kan Q and
Fan K: MMP-9-cleaved osteopontin isoform mediates tumor immune
escape by inducing expansion of myeloid-derived suppressor cells.
Biochem Biophys Res Commun. 493:1478–1484. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guarneri C, Bevelacqua V, Polesel J,
Falzone L, Cannavò PS, Spandidos DA, Malaponte G and Libra M: NF-κB
inhibition is associated with OPN/MMP 9 downregulation in cutaneous
melanoma. Oncol Rep. 37:737–746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu GX, Sun JT, Yang MX, Qi XM, Shao QQ,
Xie Q, Qu X, Wei FC and Sun SZ: OPN promotes survival of activated
T cells by up-regulating CD44 in patients with oral lichen planus.
Clin Immunol. 138:291–298. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matušan-Ilijaš K, Damante G, Fabbro D,
Dorđević G, Hadžisejdić I, Grahovac M, Marić I, Spanjol J, Grahovac
B, Jonjić N, et al: Osteopontin expression correlates with nuclear
factor-κB activation and apoptosis downregulation in clear cell
renal cell carcinoma. Pathol Res Pract. 207:104–110. 2011.
View Article : Google Scholar
|
|
30
|
Song G, Cai QF, Mao YB, Ming YL, Bao SD
and Ouyang GL: Osteopontin promotes ovarian cancer progression and
cell survival and increases HIF-1alpha expression through the
PI3-K/Akt pathway. Cancer Sci. 99:1901–1907. 2008.PubMed/NCBI
|
|
31
|
Wang HL, Ruan LH and Zhao XQ: Expression
of osteopontin and VEGF in acute leukemia and their relationship
with angiogenesis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 19:926–929.
2011.In Chinese. PubMed/NCBI
|
|
32
|
Castello LM, Raineri D, Salmi L, Clemente
N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P,
Cantaluppi V, et al: Osteopontin at the crossroads of inflammation
and tumor progression. Mediators Inflamm. 2017:40490982017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai J, Peng L, Fan K, Wang H, Wei R, Ji G,
Cai J, Lu B, Li B, Zhang D, et al: Osteopontin induces angiogenesis
through activation of PI3K/AKT and ERK1/2 in endothelial cells.
Oncogene. 28:3412–3422. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chakraborty G, Jain S and Kundu GC:
Osteopontin promotes vascular endothelial growth factor-dependent
breast tumor growth and angiogenesis via autocrine and paracrine
mechanisms. Cancer Res. 68:152–161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tilli TM, Mello KD, Ferreira LB, Matos AR,
Accioly MT, Faria PA, Bellahcène A, Castronovo V and Gimba ER: Both
osteopontin-c and osteopontin-b splicing isoforms exert
pro-tumorigenic roles in prostate cancer cells. Prostate.
72:1688–1699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nuñez-Garcia M, Gomez-Santos B, Buqué X,
García-Rodriguez JL, Romero MR, Marin JJG, Arteta B, García-Monzón
C, Castaño L, Syn WK, et al: Osteopontin regulates the cross-talk
between phosphatidylcholine and cholesterol metabolism in mouse
liver. J Lipid Res. 58:1903–1915. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Briones-Orta MA, Avendaño-Vázquez SE,
Aparicio-Bautista DI, Coombes JD, Weber GF and Syn W-K: Osteopontin
splice variants and polymorphisms in cancer progression and
prognosis. Biochim Biophys Acta Rev Cancer. 1868:93–108. 108.A2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin J, Myers AL, Wang Z, Nancarrow DJ,
Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang
TD, et al: Osteopontin (OPN/SPP1) isoforms collectively enhance
tumor cell invasion and dissemination in esophageal adenocarcinoma.
Oncotarget. 6:22239–22257. 2015.PubMed/NCBI
|
|
39
|
Choi SI, Kim SY, Lee JH, Kim JY, Cho EW
and Kim IG: Osteopontin production by TM4SF4 signaling drives a
positive feedback autocrine loop with the STAT3 pathway to maintain
cancer stem cell-like properties in lung cancer cells. Oncotarget.
8:101284–101297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sui H, Zhu L, Deng W and Li Q:
Epithelial-mesenchymal transition and drug resistance: Role,
molecular mechanisms, and therapeutic strategies. Oncol Res Treat.
37:584–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu X and Fan D: The
epithelial-mesenchymal transition and cancer stem cells: Functional
and mechanistic links. Curr Pharm Des. 21:1279–1291. 2015.
View Article : Google Scholar
|
|
43
|
Li L and Li W: Epithelial-mesenchymal
transition in human cancer: Comprehensive reprogramming of
metabolism, epigenetics, and differentiation. Pharmacol Ther.
150:33–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
46
|
Mohammadi S, Zahedpanah M, Ghaffari SH,
Shaiegan M, Nikbakht M and Nikugoftar M: Osteopontin plays a unique
role in resistance of CD34+/CD123+ human
leukemia cell lines KG1a to parthenolide. Life Sci. 189:89–95.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liersch R, Shin JW, Bayer M, Schwöppe C,
Schliemann C, Berdel WE, Mesters R and Detmar M: Analysis of a
novel highly metastatic melanoma cell line identifies osteopontin
as a new lymphangiogenic factor. Int J Oncol. 41:1455–1463.
2012.PubMed/NCBI
|
|
48
|
Yi H, Zeng D, Shen Z, Liao J, Wang X, Liu
Y, Zhang X and Kong P: Integrin alphavbeta3 enhances β-catenin
signaling in acute myeloid leukemia harboring Fms-like tyrosine
kinase-3 internal tandem duplication mutations: Implications for
micro-environment influence on sorafenib sensitivity. Oncotarget.
7:40387–40397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cao L, Fan X, Jing W, Liang Y, Chen R, Liu
Y, Zhu M, Jia R, Wang H, Zhang X, et al: Osteopontin promotes a
cancer stem cell-like phenotype in hepatocellular carcinoma cells
via an integrin-NF-κB-HIF-1α pathway. Oncotarget. 6:6627–6640.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luo SD, Chen YJ, Liu CT, Rau KM, Chen YC,
Tsai HT, Chen CH and Chiu TJ: Osteopontin involves cisplatin
resistance and poor prognosis in oral squamous cell carcinoma.
BioMed Res Int. 2015:5085872015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ng L, Wan T, Chow A, Iyer D, Man J, Chen
G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression
induced tumor progression and chemoresistance to oxaliplatin
through induction of stem-like properties in human colorectal
cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qian C, Li P, Yan W, Shi L, Zhang J, Wang
Y, Liu H and You Y: Downregulation of osteopontin enhances the
sensitivity of glioma U251 cells to temozolomide and cisplatin by
targeting the NF-κB/Bcl 2 pathway. Mol Med Rep. 11:1951–1955. 2015.
View Article : Google Scholar
|
|
53
|
Pang H, Cai L, Yang Y, Chen X, Sui G and
Zhao C: Knockdown of osteopontin chemosensitizes MDA-MB-231 cells
to cyclophosphamide by enhancing apoptosis through activating p38
MAPK pathway. Cancer Biother Radiopharm. 26:165–173. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tajima K, Ohashi R, Sekido Y, Hida T, Nara
T, Hashimoto M, Iwakami S, Minakata K, Yae T, Takahashi F, et al:
Osteopontin-mediated enhanced hyaluronan binding induces multidrug
resistance in mesothelioma cells. Oncogene. 29:1941–1951. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wohlleben G, Scherzad A, Güttler A,
Vordermark D, Kuger S, Flentje M and Polat B: Influence of hypoxia
and irradiation on osteopontin expression in head and neck cancer
and glioblastoma cell lines. Radiat Oncol. 10:1672015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ostheimer C, Schweyer F, Reese T, Bache M
and Vordermark D: The relationship between tumor volume changes and
serial plasma osteopontin detection during radical radiotherapy of
non-small-cell lung cancer. Oncol Lett. 12:3449–3456. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang M, Han J, Marcar L, Black J, Liu Q,
Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, et al: Radiation
resistance in KRAS-mutated lung cancer is enabled by stem-like
properties mediated by an osteopontin-EGFR pathway. Cancer Res.
77:2018–2028. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chang SH, Minai-Tehrani A, Shin JY, Park
S, Kim JE, Yu KN, Hong SH, Hong CM, Lee KH, Beck GR Jr, et al:
Beclin1-induced autophagy abrogates radioresistance of lung cancer
cells by suppressing osteopontin. J Radiat Res (Tokyo). 53:422–432.
2012. View Article : Google Scholar
|
|
59
|
Huang X, Qian Y, Wu H, Xie X, Zhou Q, Wang
Y, Kuang W, Shen L, Li K, Su J, et al: Aberrant expression of
osteopontin and E-cadherin indicates radiation resistance and poor
prognosis for patients with cervical carcinoma. J Histochem
Cytochem. 63:88–98. 2015. View Article : Google Scholar :
|
|
60
|
Pietras A, Katz AM, Ekström EJ, Wee B,
Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT and
Holland EC: Osteopontin-CD44 signaling in the glioma perivascular
niche enhances cancer stem cell phenotypes and promotes aggressive
tumor growth. Cell Stem Cell. 14:357–369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
van Staalduinen J, Baker D, Ten Dijke P
and van Dam H: Epithelial-mesenchymal-transition-inducing
transcription factors: New targets for tackling chemoresistance in
cancer? Oncogene. Jul 12–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cichon MA and Radisky DC: ROS-induced
epithelial-mesenchymal transition in mammary epithelial cells is
mediated by NF-κB-dependent activation of Snail. Oncotarget.
5:2827–2838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kothari AN, Arffa ML, Chang V, Blackwell
RH, Syn WK, Zhang J, Mi Z and Kuo PC: Osteopontin-A Master
Regulator of Epithelial-Mesenchymal Transition. J Clin Med.
5:52016. View Article : Google Scholar
|
|
67
|
Yu X, Zheng Y, Zhu X, Gao X, Wang C, Sheng
Y, Cheng W, Qin L, Ren N, Jia H, et al: Osteopontin promotes
hepatocellular carcinoma progression via the PI3K/AKT/Twist
signaling pathway. Oncol Lett. 16:5299–5308. 2018.PubMed/NCBI
|
|
68
|
Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD
and Kuo PC: Osteopontin up-regulates critical
epithelial-mesenchymal transition transcription factors to induce
an aggressive breast cancer phenotype. J Am Coll Surg. 217:17–26.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei
J, Sheng Y, Zheng Y, Yu J, Xie L, et al: Osteopontin promotes
epithelial-mesenchymal transition of hepatocellular carcinoma
through regulating vimentin. Oncotarget. 7:12997–13012. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Weber CE, Li NY, Wai PY and Kuo PC:
Epithelial-mesenchymal transition, TGF-β, and osteopontin in wound
healing and tissue remodeling after injury. J Burn Care Res.
33:311–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jia R, Liang Y, Chen R, Liu G, Wang H,
Tang M, Zhou X, Wang H, Yang Y, Wei H, et al: Osteopontin
facilitates tumor metastasis by regulating epithelial-mesenchymal
plasticity. Cell Death Dis. 7:e25642016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zahed Panah M, Nikbakht M, Sajjadi SM,
Rostami S, Norooznezhad AH, Kamranzadeh Fumani H, Ghavamzadeh A and
Mohammadi S: Anti-apoptotic effects of osteopontin via the
up-regulation of AKT/mTOR/β-catenin loop in acute myeloid leukemia
cells. Int J Hematol Oncol Stem Cell Res. 11:148–157.
2017.PubMed/NCBI
|
|
73
|
Li X, Jiang Z, Li X and Zhang X: SIRT1
overexpression protects non-small cell lung cancer cells against
osteopontin-induced epithelial-mesenchymal transition by
suppressing NF-κB signaling. OncoTargets Ther. 11:1157–1171. 2018.
View Article : Google Scholar
|
|
74
|
Castellano G, Malaponte G, Mazzarino MC,
Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S
and Libra M: Activation of the osteopontin/matrix
metalloproteinase-9 pathway correlates with prostate cancer
progression. Clin Cancer Res. 14:7470–7480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tan TK, Zheng G, Hsu TT, Lee SR, Zhang J,
Zhao Y, Tian X, Wang Y, Wang YM, Cao Q, et al: Matrix
metalloproteinase-9 of tubular and macrophage origin contributes to
the pathogenesis of renal fibrosis via macrophage recruitment
through osteopontin cleavage. Lab Invest. 93:434–449. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Yang MC, Wang HC, Hou YC, Tung HL, Chiu TJ
and Shan YS: Blockade of autophagy reduces pancreatic cancer stem
cell activity and potentiates the tumoricidal effect of
gemcitabine. Mol Cancer. 14:1792015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Huang G, Du M-Y, Zhu H, Zhang N, Lu ZW,
Qian LX, Zhang W, Tian X, He X and Yin L: MiRNA-34a reversed
TGF-β-induced epithelial-mesenchymal transition via suppression of
SMAD4 in NPC cells. Biomed Pharmacother. 106:217–224. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Cui H, Zhang AJ, Chen M and Liu JJ: ABC
transporter inhibitors in reversing multidrug resistance to
chemotherapy. Curr Drug Targets. 16:1356–1371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhang F, Luo W, Li Y, Gao S and Lei G:
Role of osteopontin in rheumatoid arthritis. Rheumatol Int.
35:589–595. 2015. View Article : Google Scholar
|
|
80
|
Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J,
King JA and Samant RS: Spheroid-forming subpopulation of breast
cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p
regulated de novo expression of osteopontin. J Cell Mol Med.
14:1693–1706. 2010. View Article : Google Scholar
|
|
81
|
Bhattacharya SD, Mi Z, Kim VM, Guo H,
Talbot LJ and Kuo PC: Osteopontin regulates epithelial mesenchymal
transition-associated growth of hepatocellular cancer in a mouse
xenograft model. Ann Surg. 255:319–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang J, Yang M, Li Y and Han B: The role
of microRNAs in the chemoresistance of breast cancer. Drug Dev Res.
76:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Liang J, Xu L, Zhou F, Liu AM, Ge HX, Chen
YY and Tu M: MALAT1/miR-127-5p regulates osteopontin (OPN)-mediated
proliferation of human chondrocytes through PI3K/Akt pathway. J
Cell Biochem. 119:431–439. 2018. View Article : Google Scholar
|
|
84
|
Boguslawska J, Sokol E, Rybicka B, Czubaty
A, Rodzik K and Piekielko-Witkowska A: microRNAs target SRSF7
splicing factor to modulate the expression of osteopontin splice
variants in renal cancer cells. Gene. 595:142–149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL,
Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, et al: Lentiviral-mediated
miRNA against osteopontin suppresses tumor growth and metastasis of
human hepatocellular carcinoma. Hepatology. 48:1834–1842. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hunter C, Bond J, Kuo PC, Selim MA and
Levinson H: The role of osteopontin and osteopontin aptamer
(OPN-R3) in fibroblast activity. J Surg Res. 176:348–358. 2012.
View Article : Google Scholar :
|
|
87
|
Talbot LJ, Mi Z, Bhattacharya SD, Kim V,
Guo H and Kuo PC: Pharmacokinetic characterization of an RNA
aptamer against osteopontin and demonstration of in vivo efficacy
in reversing growth of human breast cancer cells. Surgery.
150:224–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mirzaei A, Mohammadi S, Ghaffari SH,
Nikbakht M, Bashash D, Alimoghaddam K and Ghavamzadeh A:
Osteopontin b and c isoforms: Molecular Candidates Associated with
Leukemic Stem Cell Chemoresistance in Acute Myeloid Leukemia. Asian
Pac J Cancer Prev. 18:1707–1715. 2017.PubMed/NCBI
|
|
89
|
Nakamura KDM, Tilli TM, Wanderley JL,
Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE and
Gimba ER: Osteopontin splice variants expression is involved on
docetaxel resistance in PC3 prostate cancer cells. Tumour Biol.
37:2655–2663. 2016. View Article : Google Scholar
|
|
90
|
Zduniak K, Ziolkowski P, Ahlin C, Agrawal
A, Agrawal S, Blomqvist C, Fjällskog ML and Weber GF: Nuclear
osteopontin-c is a prognostic breast cancer marker. Br J Cancer.
112:729–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ortiz-Martínez F, Perez-Balaguer A,
Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI,
Lerma E and Peiró G: Association of increased osteopontin and
splice variant-c mRNA expression with HER2 and
triple-negative/basal-like breast carcinomas subtypes and
recurrence. Hum Pathol. 45:504–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Patani N, Jiang W and Mokbel K:
Osteopontin C mRNA expression is associated with a poor clinical
outcome in human breast cancer. Int J Cancer. 122:26462008.
View Article : Google Scholar : PubMed/NCBI
|
